These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 27782084)

  • 41. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
    Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
    Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Measles virus: a future therapeutic agent in oncology?].
    Touchefeu Y; Schick U; Harrington KJ
    Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
    Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
    Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role of Neutrophils in Measles Virus-mediated Oncolysis Differs Between B-cell Malignancies and Is Not Always Enhanced by GCSF.
    Dey A; Zhang Y; Castleton AZ; Bailey K; Beaton B; Patel B; Fielding AK
    Mol Ther; 2016 Feb; 24(1):184-92. PubMed ID: 26278331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.
    Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J
    J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses.
    Weiland T; Lampe J; Essmann F; Venturelli S; Berger A; Bossow S; Berchtold S; Schulze-Osthoff K; Lauer UM; Bitzer M
    Int J Cancer; 2014 Jan; 134(1):235-43. PubMed ID: 23797800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
    Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
    Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.
    Dispenzieri A; Tong C; LaPlant B; Lacy MQ; Laumann K; Dingli D; Zhou Y; Federspiel MJ; Gertz MA; Hayman S; Buadi F; O'Connor M; Lowe VJ; Peng KW; Russell SJ
    Leukemia; 2017 Dec; 31(12):2791-2798. PubMed ID: 28439108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptome Analysis of Human Glioblastoma Cells Susceptible to Infection with the Leningrad-16 Vaccine Strain of Measles Virus.
    Ammour Y; Susova O; Krasnov G; Nikolaeva E; Varachev V; Schetinina Y; Gavrilova M; Mitrofanov A; Poletaeva A; Bekyashev A; Faizuloev E; Zverev VV; Svitich OA; Nasedkina TV
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
    Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
    PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Viral oncolysis - can insights from measles be transferred to canine distemper virus?
    Lapp S; Pfankuche VM; Baumgärtner W; Puff C
    Viruses; 2014 Jun; 6(6):2340-75. PubMed ID: 24921409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
    Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
    Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Measles as a potential oncolytic virus.
    Fielding AK
    Rev Med Virol; 2005; 15(2):135-42. PubMed ID: 15546127
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Small molecules baicalein and cinnamaldehyde are potentiators of measles virus-induced breast cancer oncolysis.
    Kuo YT; Liu CH; Wong SH; Pan YC; Lin LT
    Phytomedicine; 2021 Aug; 89():153611. PubMed ID: 34144429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A mathematical model of oncolytic virotherapy with time delay.
    Wang ZZ; Guo ZM; Smith H
    Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
    Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
    Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.
    Aref S; Castleton AZ; Bailey K; Burt R; Dey A; Leongamornlert D; Mitchell RJ; Okasha D; Fielding AK
    Mol Ther; 2020 Apr; 28(4):1043-1055. PubMed ID: 32087150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.